@article{MTMT:34501723,
	title = {Low-Dose vs Standard-Dose Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplantation: A Single-Center Retrospective Analysis},
	url = {https://m2.mtmt.hu/api/publication/34501723},
	author = {Farkas, Katalin and Varga, Marina and Dinnyes, Izabella and Rem, Lili and Telkes, Gábor and Wágner, László József and Remport, Ádám and Piros, László and Szijártó, Attila and Huszty, Gergely},
	doi = {10.1016/j.transproceed.2023.11.021},
	journal-iso = {TRANSPLANT PROC},
	journal = {TRANSPLANTATION PROCEEDINGS},
	volume = {56},
	unique-id = {34501723},
	issn = {0041-1345},
	abstract = {Prophylactic administration of valganciclovir (VG) is an accepted method for the prevention of cytomegalovirus (CMV) infection after kidney transplantation (KTx). The standard dosage of oral VG is 900 mg/day, adjusted to renal function. There is growing evidence that low-dose 450 mg/day VG might be safe and effective. We compared low-dose vs standard-dose prophylaxis after KTx in a single-center follow-up study.Data from 603 renal transplantations at a single center were retrospectively analyzed (2011-2014, 12-month follow-up). Recipients with donor IgG positive-recipient IgG positive (D+/R+), (D+/R-), and (D-/R+) CMV serostatus were routinely treated with 450 mg/day VG for 3 months. Based on the same prophylactic dose, patients could be categorized into two groups according to their postoperative renal function: those receiving standard-dose VG due to a lower estimated glomerular filtration rate (eGFR) (average eGFR<60 mL/min/1.73 m2) and those receiving low-dose VG due to higher eGFR (average eGFR>60 mL/min/1.73 m2).Estimated glomerular filtration rate-based VG serum alterations significantly affected the risk of CMV infection with a higher incidence in higher VG levels (standard-dose: 357 patients, CMV: 33 cases (9.2 %); low-dose: 246 patients, CMV: 10 cases (4.1%). The occurrence of known risk factors: serologic risk distribution and rate of induction therapy were not statistically different between the 2 groups. Treatment of an acute rejection episode influenced the infection rate significantly in the standard-dose group. As a side effect of prophylaxis, leucopenia (<3G/L) was 2.46 times higher in standard-dose vs low-dose group.Low-dose VG administration is safe and non-inferior to the standard dose in the prophylaxis of CMV infection after KTx.},
	year = {2024},
	eissn = {1873-2623},
	pages = {105-110},
	orcid-numbers = {Varga, Marina/0000-0002-6192-8940; Telkes, Gábor/0000-0002-1551-5029; Wágner, László József/0000-0001-6806-4076; Piros, László/0000-0003-4841-220X}
}

@{MTMT:34538815,
	title = {Transzplantációs alapismeretek},
	url = {https://m2.mtmt.hu/api/publication/34538815},
	author = {Huszty, Gergely and Kóbori, László and Piros, László},
	booktitle = {Sebészet tankönyv és tudománytörténet: traumatológiai, szülészeti és urológiai alapismeretekkel kiegészítve},
	unique-id = {34538815},
	year = {2023},
	pages = {527-532},
	orcid-numbers = {Kóbori, László/0000-0002-4843-6650; Piros, László/0000-0003-4841-220X}
}

@article{MTMT:34422426,
	title = {Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?},
	url = {https://m2.mtmt.hu/api/publication/34422426},
	author = {Huszty, Gergely and Igaz, Péter},
	doi = {10.1530/ERC-23-0220},
	journal-iso = {ENDOCR-RELAT CANCER},
	journal = {ENDOCRINE-RELATED CANCER},
	volume = {31},
	unique-id = {34422426},
	issn = {1351-0088},
	year = {2023},
	eissn = {1479-6821},
	orcid-numbers = {Igaz, Péter/0000-0003-2192-554X}
}

@article{MTMT:34167039,
	title = {A peritoneális felszín tumorainak sebészete – citoreduktív sebészet és hipertermiás intraperitoneális kemoterápia},
	url = {https://m2.mtmt.hu/api/publication/34167039},
	author = {Huszty, Gergely and Bihari, László and Gráf, László and Szijártó, Attila and Máté, Szabolcs},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {67},
	unique-id = {34167039},
	issn = {0025-0244},
	abstract = {Peritoneal carcinosis has historically been considered as inoperable, although the technique of its resesection together with high dose intraperitoneal chemotherapy potentiated by heat has been described decades ago. It has not became a widely practiced routine except in specialized centers - the complex technique, weakly standardized but resource demanding chemotherapy, lacking financial background and the many times questionable clinical benefit at a cost of high surgical load might have been the key factors. Refined technology, developing chemotherapy protocols together with growing clinical evidence are now more sharply delineating the range of indications where the procedure might be beneficial, increases survival, or is the only curative therapy. These include tumors of the appendix and pseudomyxoma peritonei, mesothelioma, and selected cases of ovarian, colorectal and gastric cancer. In addition to technical description of the intervention, we summarize the currently valid indications and describe our institutional protocol for the treatment of appendiceal malignancies.},
	year = {2023},
	eissn = {2060-0399},
	pages = {247-258}
}

@article{MTMT:34081713,
	title = {Parathyroid cancer with MTOR gene mutation. Case report and review of the literature},
	url = {https://m2.mtmt.hu/api/publication/34081713},
	author = {Stark, Júlia and Tőke, Judit and Huszty, Gergely and Nagy, Péter and Bedics, Gábor and Bödör, Csaba and Tímár, József and Tóth, Miklós},
	doi = {10.1016/j.ando.2023.06.003},
	journal-iso = {ANN ENDOCRINOL-PARIS},
	journal = {ANNALES D ENDOCRINOLOGIE},
	volume = {84},
	unique-id = {34081713},
	issn = {0003-4266},
	year = {2023},
	eissn = {2213-3941},
	pages = {761-763},
	orcid-numbers = {Nagy, Péter/0000-0002-1664-9221; Bedics, Gábor/0000-0003-4628-2384; Bödör, Csaba/0000-0002-0729-692X; Tímár, József/0000-0001-9183-0859; Tóth, Miklós/0000-0002-8701-408X}
}

@article{MTMT:33271361,
	title = {Optimizing Survival for Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Report and Current Perspectives},
	url = {https://m2.mtmt.hu/api/publication/33271361},
	author = {Nagy, Gergely and Gerlei, Zsuzsanna and Haboub-Sandil, Anita and Görög, Dénes and Szabó, József and Kóbori, László and Huszty, Gergely and Bihari, László and Rózsa, Balázs and Pőcze, Balázs and Máthé, Zoltán and Piros, László},
	doi = {10.1016/j.transproceed.2022.10.048},
	journal-iso = {TRANSPLANT PROC},
	journal = {TRANSPLANTATION PROCEEDINGS},
	volume = {54},
	unique-id = {33271361},
	issn = {0041-1345},
	abstract = {Hepatocellular carcinoma (HCC) is the leading primary liver tumor and a main indication for transplant. Transplant criteria are based on clinicopathologic features, meanwhile adequate downstaging and molecular mechanisms are getting more attention in evolving therapeutic algorithm of HCC. The aim of our study was to overview the results of the Hungarian Liver Transplant Program in the field of HCC and introduce new aspects of personalized treatment options.We performed retrospective analysis of survival and tumor recurrence of HCC-associated liver transplant recipients between October 2013 and December 2020. Patients were categorized in Milan criteria (MC), beyond MC but within University of California, San Francisco (UCSF), and beyond UCSF criteria groups after pathologic examination of the explanted liver. Demographic data and preoperative locoregional treatments were assessed.A total of 529 primer liver transplants were performed, 88 because of HCC. A total of 87 patients had underlying cirrhosis because of hepatitis C (54%), alcohol-related liver disease (33.7%), hepatitis B (4.5%), or unknown etiology. A total of 55.6% of the patients had at least one locoregional treatment. A total of 67.4% of the patients were within MC, 5.6% were within UCSF criteria, and 27% were beyond UCSF criteria. The 1-, 3-, and 5-year survival rates were 80%, 79%, and 75%. The outcome was better in early-stage tumors, but the difference was not significant (P = .745) CONCLUSIONS: The favorable survival in our department legitimates the strict transplant criteria of HCC. Adequate locoregional therapy as downstaging can expand recipient pool. Molecular tumor profiling may lead to personalized treatment of HCC.},
	year = {2022},
	eissn = {1873-2623},
	pages = {2593-2597},
	orcid-numbers = {Nagy, Gergely/0000-0001-8660-7687; Görög, Dénes/0000-0002-4216-6282; Kóbori, László/0000-0002-4843-6650; Máthé, Zoltán/0000-0002-7835-5077; Piros, László/0000-0003-4841-220X}
}

@article{MTMT:33257643,
	title = {Graft Arterial Dissection and Thrombosis After Kidney Transplantation With Undiagnosed Fibromuscular Dysplasia From a Deceased Donor: Case Report and Review},
	url = {https://m2.mtmt.hu/api/publication/33257643},
	author = {Meltzer, Anna Zsófia and Fintha, Attila and Cseprekál, Orsolya and Somogyi, Dóra and Szabó, József and Kóbori, László and Rózsa, Balázs and Piros, László and Huszty, Gergely},
	doi = {10.1016/j.transproceed.2022.10.049},
	journal-iso = {TRANSPLANT PROC},
	journal = {TRANSPLANTATION PROCEEDINGS},
	volume = {54},
	unique-id = {33257643},
	issn = {0041-1345},
	abstract = {Fibromuscular dysplasia (FMD), a relatively frequent arterial deformity with an estimated prevalence of 2% to 6% has been sporadically reported during deceased donor kidney donations. Only 8 case reports are available in the previous literature.In our work, implantation of 2 kidneys from the same deceased donor with macroscopically evident and later histologically confirmed FMD are presented, one of which ended up as acute arterial complication. Renal arteries were cut short to allow safe implantation, but arterial dissection and thrombosis led to graft loss in the early perioperative period in the latter case.Although resection of the arterial segments affected by FMD as a routine may allow implantation, macroscopically healthy-looking arteries might still be affected and thus carry elevated postoperative risk. The aim of our case report is to make proposal for an onsite diagnosis of FMD in case of clinical suspicion.},
	year = {2022},
	eissn = {1873-2623},
	pages = {2603-2607},
	orcid-numbers = {Fintha, Attila/0000-0002-0519-8170; Cseprekál, Orsolya/0000-0003-2867-3875; Kóbori, László/0000-0002-4843-6650; Piros, László/0000-0003-4841-220X}
}

@article{MTMT:33153589,
	title = {Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series},
	url = {https://m2.mtmt.hu/api/publication/33153589},
	author = {Tőke, Judit and Uhlyarik, Andrea and Lohinszky, Júlia and Stark, Júlia and Huszty, Gergely and Micsik, Tamás and Borka, Katalin and Reismann, Péter and Horányi, János and Igaz, Péter and Tóth, Miklós},
	doi = {10.3389/fendo.2022.952418},
	journal-iso = {FRONT ENDOCRINOL},
	journal = {FRONTIERS IN ENDOCRINOLOGY},
	volume = {13},
	unique-id = {33153589},
	issn = {1664-2392},
	abstract = {<sec>ObjectivesThis study aimed to characterise the clinicopathological features and prognostic factors of a large cohort of Hungarian patients with adrenocortical cancer diagnosed between 2000-2021.</sec><sec>Patients and methodsThis retrospective study included seventy-four patients (27 men and 47 women) with histologically confirmed adrenocortical cancer in a single tertiary referral endocrine centre. Descriptive statistics were performed, providing summaries of selected clinical and pathological parameters. Clinicopathological factors contributing to overall survival were analysed.</sec><sec>ResultsThe median age of patients was 48,5 years (17-84 years) at diagnosis. The majority of cases were diagnosed at ENSAT stage II (39,2%) and stage IV (33,8%). At diagnosis, the median tumour size was 9,0 cm (4,5-20 cm). In 47 patients (71,6%), the tumour was hormonally active. The median overall survival and the 5-year survival rate were 23,5 months (95% CI, 17-30,5 months) and 18,3%, respectively. Primary tumour resection was performed in 68 patients (91,8%); R0 surgical resection was achieved in 30 patients. In univariate Cox regression model, tumours with stages III and IV, high proliferative activity (Ki67-index > 10%), R1-R2 surgical resection state and hormonal activity were associated with poorer survival. Cortisol excess, both isolated and combined with androgen production, was associated with poorer survival. Fifty-five patients were treated with mitotane. The overall survival of patients achieving therapeutic mitotane plasma concentration was significantly better compared to those who never reached it [27.0 (2-175) months vs 18.0 (2-83) months; p<0.05)]. The median age, the distribution of gender, ENSAT stage, resection state and Ki67-index did not differ between these two groups. The time needed to reach the therapeutic range of serum mitotane was 96.5 days (95% CI, 75-133 days).</sec><sec>ConclusionOur results confirm previous data that disease stage, mitotic activity, the resection state and the mitotane treatment achieving therapeutic concentration are the most critical parameters influencing the prognosis of adrenocortical cancer. Our data suggest that hormonal activity may be more frequent than described previously, and it is a strong and independent prognostic factor of overall survival. To our knowledge, this is the first single-centre study confirming the prognostic importance of achieving therapeutic mitotane concentration.</sec>},
	year = {2022},
	eissn = {1664-2392},
	orcid-numbers = {Borka, Katalin/0000-0002-8956-0770; Reismann, Péter/0000-0002-2696-6132; Igaz, Péter/0000-0003-2192-554X; Tóth, Miklós/0000-0002-8701-408X}
}

@misc{MTMT:33105564,
	title = {CMV profilaxis alacsony dózisú valganciclovirrel vesetranszplantáció után},
	url = {https://m2.mtmt.hu/api/publication/33105564},
	author = {Farkas, Katalin and Huszty, Gergely and Varga, Marina and Telkes, Gábor and Cseprekál, Orsolya and Marton, Adrienn and Dinnyés, Izabella and Rem, Lili and Szijártó, Attila},
	unique-id = {33105564},
	year = {2022},
	orcid-numbers = {Telkes, Gábor/0000-0002-1551-5029; Cseprekál, Orsolya/0000-0003-2867-3875}
}

@article{MTMT:32545013,
	title = {Surprising genetic and pathological findings in a patient with giant bilateral periadrenal tumours: PEComas and mutations of PTCH1 in Gorlin-Goltz syndrome},
	url = {https://m2.mtmt.hu/api/publication/32545013},
	author = {Igaz, Péter and Toth, Geza and Nagy, Péter and Dezső, Katalin and Turai, Péter István and Medvecz, Márta and Wikonkál, Norbert and Huszty, Gergely and Piros, László and Tóth, Erika and Bozsik, Anikó and Likó, István and Patócs, Attila Balázs and Butz, Henriett},
	doi = {10.1136/jmedgenet-2021-108082},
	journal-iso = {JMG},
	journal = {JOURNAL OF MEDICAL GENETICS},
	volume = {59},
	unique-id = {32545013},
	issn = {0022-2593},
	year = {2022},
	eissn = {1468-6244},
	pages = {916-919},
	orcid-numbers = {Igaz, Péter/0000-0003-2192-554X; Nagy, Péter/0000-0002-1664-9221; Dezső, Katalin/0000-0002-4856-0483; Turai, Péter István/0000-0003-2765-2351; Medvecz, Márta/0000-0002-3126-096X; Wikonkál, Norbert/0000-0003-4949-8711; Piros, László/0000-0003-4841-220X; Tóth, Erika/0000-0003-2054-8447; Bozsik, Anikó/0000-0001-5410-9173; Likó, István/0000-0001-7668-4726; Patócs, Attila Balázs/0000-0001-7506-674X; Butz, Henriett/0000-0003-1664-409X}
}